CDTX News and Press, Cidara Therapeutics Inc. From 09/03/19

Thinly traded nano cap Cidara Therapeutics (NASDAQ: CDTX ) is up  77%  premarket on increased volume, albeit in turnover of only 92K shares, in response to its agreement with Mundipharma to develop and commercialize rezafungin, a once-weekly echinocandin antifungal, for the first...

Collaboration combines strengths to develop and commercialize life-saving antifungal treatment and prophylaxis, an area of high unmet medical need Mundipharma acquires exclusive rights to develop and commercialize rezafungin in all markets outside of the United States and Japan, wh...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that five abstracts, including one late-breaker, highlighting data from its Cloudbreak ® antiviral program have been accepted for presentation at...

The following slide deck was published by Cidara Therapeutics, Inc. in conjunction with this Read more ...

Cidara Therapeutics (NASDAQ: CDTX ): Q2 GAAP EPS of -$0.49 beats by $0.08 . Cash, cash equivalents and short-term investments of $44.3M Press Release More news on: Cidara Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives, including immunotherapies, today reported financial results for the three months ended June 30, 2019 and provided an update on its corporate ...

SAN DIEGO, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at t...

Thinly traded nano cap Cidara Therapeutics ( CDTX +12.5% ) is up on more than a 10x surge in volume in early trade in response to a positive outcome from Part B of its Phase 2 STRIVE study evaluating antifungal rezafungin in patients with candidemia and/or invasive candidiasis. More ...

Medley Management (NYSE: MDLY ) +35%  as Sierra, Medley Capital, Medley Management amend merger deals . More news on: Medley Management Inc., Sintx Technologies, Inc., NovaBay Pharmaceuticals, Inc., Stocks on the move, Read more ...

Data from second part of successful Phase 2 STRIVE trial further substantiate the efficacy, safety and tolerability of once-weekly rezafungin for first-line treatment of invasive Candida infections Global Phase 3 ReSTORE trial ongoing Company to host conference call today at 8...